Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of the American College of Cardiology

• Publication date

  2010-07-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jacc.2010.05.011PMID 20650361PMCID PMC4523221
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of Enalapril on Clinical Status, Biochemistry,Exercise Performance and Haemodynamics in Heart Failure

  2012cited by this paper
• WITHDRAWAL OF DIGOXIN FROM PATIENTS WITH CHRONIC HEART FAILURE TREATED WITH ANGIOTENSIN CONVERTING ENZYME INHIBITORS

  2010cited by this paper
• Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction.

  2007cited by this paper
• Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT.

  2007cited by this paper
• Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.

  2007cited by this paper
• Clinical Features and Outcome of Patients with Apical Hypertrophic Cardiomyopathy in Taiwan

  2006cited by this paper
• Congestive heart failure

  2006cited by this paper
• The effect of beta-adrenergic receptor antagonism in cardiac sympathetic neuronal remodeling in patients with heart failure.

  2006cited by this paper
• The effect of β-adrenergic receptor antagonism in cardiac sympathetic neuronal remodeling in patients with heart failure

  2006cited by this paper
• Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure

  2005cited by this paper
• Left Ventricular Diastolic Function Improvement by Carvedilol Therapy in Advanced Heart Failure

  2005cited by this paper
• The effect of cardiac resynchronization on morbidity and mortality in heart failure.

  2005cited by this paper
• A controlled study of the effects of carvedilol on clinical events, left ventricular function and proinflammatory cytokines levels in patients with dilated cardiomyopathy.

  2005cited by this paper
• Clinical trials update from the European Society of Cardiology meeting 2005: CARE‐HF extension study, ESSENTIAL, CIBIS‐III, S‐ICD, ISSUE‐2, STRIDE‐2, SOFA, IMAGINE, PREAMI, SIRIUS‐II and ACTIVE

  2005cited by this paper
• Effects of Cardiac Resynchronization on Disease Progression in Patients With Left Ventricular Systolic Dysfunction, an Indication for an Implantable Cardioverter-Defibrillator, and Mildly Symptomatic Chronic Heart Failure

  2004cited by this paper
• Beneficial effects of carvedilol on angiotensin‐converting enzyme activity and renin plasma levels in patients with chronic heart failure

  2004cited by this paper
• Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: a cardiovascular magnetic resonance study

  2004cited by this paper
• Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.

  2004cited by this paper
• Targeted Anticytokine Therapy in Patients With Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)

  2004cited by this paper
• Mean body weight, height, and body mass index, United States 1960-2002.

  2004cited by this paper
• Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial.

  2004cited by this paper
• Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial.

  2004cited by this paper
• Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data.

  2004cited by this paper
• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.

  2003cited by this paper
• Adverse mortality effect of central sympathetic inhibition with sustained‐release moxonidine in patients with heart failure (MOXCON)

  2003cited by this paper
• Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure

  2003cited by this paper
• Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias.

  2003cited by this paper
• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.

  2003cited by this paper
• Ventricular remodeling in heart failure: a credible surrogate endpoint.

  2003cited by this paper
• Left ventricular remodelling and haemodynamic effects of multisite biventricular pacing in patients with left ventricular systolic dysfunction and activation disturbances in sinus rhythm: sub-study of the MUSTIC (Multisite Stimulationin Cardiomyopathies) trial.

  2003cited by this paper
• Effect of Cardiac Resynchronization Therapy on Left Ventricular Size and Function in Chronic Heart Failure

  2003cited by this paper
• Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial.

  2003cited by this paper
• Measuring inconsistency in meta-analyses

  2003cited by this paper
• Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure.

  2002cited by this paper
• Effects of Sustained-Release Moxonidine, an Imidazoline Agonist, on Plasma Norepinephrine in Patients With Chronic Heart Failure

  2002cited by this paper
• Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study.

  2002cited by this paper
• Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?

  2002cited by this paper
• Quantifying heterogeneity in a meta‐analysis

  2002cited by this paper
• Surrogate end points in heart failure.

  2002cited by this paper
• Effects of Long-Term Biventricular Stimulation for Resynchronization on Echocardiographic Measures of Remodeling

  2002cited by this paper
• Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunction.

  2002cited by this paper
• Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure

  2002cited by this paper
• Beneficial effects of metoprolol on myocardial sympathetic function: Evidence from a randomized, placebo-controlled study in patients with congestive heart failure.

  2002cited by this paper
• Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)

  2002cited by this paper
• The effect of chronic digitalization on pump function in systolic heart failure

  2001cited by this paper
• Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.

  2001cited by this paper
• Effect of carvedilol on survival in severe chronic heart failure.

  2001cited by this paper
• Results of Targeted Anti–Tumor Necrosis Factor Therapy With Etanercept (ENBREL) in Patients With Advanced Heart Failure

  2001cited by this paper
• Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure.

  2001cited by this paper
• A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

  2001cited by this paper
• A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure.

  2001cited by this paper
• Effects of carvedilol on left ventricular regional wall motion in patients with heart failure caused by ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.

  2000cited by this paper
• Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy : the randomized evaluation of strategies for left ventricular dysfunction pilot study.

  2000cited by this paper
• [Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure].

  2000cited by this paper
• EFFECT OF AMLODIPINE ON MORBIDITY AND MORTALITY IN SEVERE CHRONIC HEART FAILURE

  2000cited by this paper
• Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure.

  2000cited by this paper
• The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

  2000cited by this paper
• Felodipine improves left ventricular emptying in patients with chronic heart failure: V-HeFT III echocardiographic substudy of multicenter reproducibility and detecting functional change.

  2000cited by this paper
• Design of Phase II trials in congestive heart failure

  2000cited by this paper
• Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.

  2000cited by this paper
• Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group.

  2000cited by this paper
• Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients with Heart Failure: The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)

  2000cited by this paper
• Effect of mibefradil, a T-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure: the MACH-1 study. Mortality Assessment in Congestive Heart Failure Trial.

  2000cited by this paper
• Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction.

  2000cited by this paper
• Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling.

  2000cited by this paper
• Design of phase II trials in congestive heart failure.

  2000cited by this paper
• Left ventricular remodeling after myocardial infarction: pathophysiology and therapy.

  2000cited by this paper
• Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure.

  1999cited by this paper
• Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvedilol.

  1999cited by this paper
• The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

  1999cited by this paper
• The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.

  1999cited by this paper
• Are drug-induced changes in left ventricular ejection fraction or volumes adequate surrogates for long-term natural history outcomes in heart failure?

  1999cited by this paper
• Metoprolol CR/XL in patients with heart failure: A pilot study examining the tolerability, safety, and effect on left ventricular ejection fraction.

  1999cited by this paper
• Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group.

  1999cited by this paper
• Quantitative Synthesis in Systematic Reviews

  1997cited by this paper
• Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial.

  1997cited by this paper
• Meta-analysis for the evaluation of potential surrogate markers.

  1997cited by this paper
• Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group.

  1997cited by this paper
• Safety and efficacy of carvedilol in severe heart failure

  1997cited by this paper
• Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS).

  1997cited by this paper
• Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group.

  1997cited by this paper
• Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators.

  1997cited by this paper
• Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.

  1997cited by this paper
• The effect of digoxin on mortality and morbidity in patients with heart failure.

  1997cited by this paper
• Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease

  1997cited by this paper
• Surrogate End Points in Clinical Trials: Are We Being Misled?

  1996cited by this paper
• Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group.

  1996cited by this paper
• Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

  1996cited by this paper
• Which patient benefits from early angiotensin-converting enzyme inhibition after myocardial infarction? Results of one-year serial echocardiographic follow-up from the Captopril and Thrombolysis Study (CATS).

  1996cited by this paper
• Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy.

  1996cited by this paper
• The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

  1996cited by this paper
• Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure.

  1996cited by this paper
• Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group.

  1996cited by this paper
• Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise.

  1996cited by this paper
• Placebo controlled trial of felodipine in patients with mild to moderate heart failure. UK Study Group.

  1995cited by this paper
• Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study.

  1995cited by this paper
• Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure.

  1995cited by this paper
• Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy.

  1995cited by this paper
• The Handbook of Research Synthesis

  1995cited by this paper
• Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.

  1995cited by this paper

• Preclinical Heart Failure: A Dynamic Trajectory of Progression, Regression, and Risk.

  2026cites this paper
• Systemic immune-inflammation index, neutrophil to high-density lipoprotein ratio and pre-hospital delay: promising biomarkers for predicting the prognosis of patients with acute ST-elevation myocardial infarction.

  2026cites this paper
• A report on the successful sparing of the entire anterior mitral leaflet through the implementation of a customized procedure in the context of mitral valve replacement.

  2026cites this paper
• Association between treatment-induced changes in the Kansas City Cardiomyopathy Questionnaire and clinical outcomes in chronic heart failure: a trial-level meta-regression analysis

  2026cites this paper
• Predictors of reverse cardiac remodeling after sacubitril/valsartan in heart failure with reduced ejection fraction

  2026cites this paper
• Functional and Quality of Life Outcomes in Heart Failure Patients at a Specialized Heart Failure Clinic in Dhaka, Bangladesh

  2025cites this paper
• SGLT2 Inhibitors Are Associated with Left Ventricular Reverse Remodeling in Patients with Non-Compaction Cardiomyopathy—A Prospective Observational Cohort Trial

  2025cites this paper
• Umbilical Cord Matrix (Wharton Jelly) Mesenchymal Stem Cells in Next-Generation Myocardial Repair and Regeneration: Mechanisms and Pre-Clinical Evidence.

  2025cites this paper
• Clinical Outcomes of Catheter Ablation for Atrial Fibrillation in Patients with Acute Decompensated Heart Failure

  2025cites this paper
• The Connection Between Cognitive and Cardiac Function Following Kidney Transplant: The VINTAGE Study

  2025cites this paper
• Insights into the Benefits of Reverse Remodeling from an Echocardiographic Pressure/Volume Loop Model in Patients With Heart Failure Treated With Sacubitril/Valsartan.

  2025cites this paper
• Association Between Improvement in Left Ventricular Ejection Fraction and Prognosis of Patients with Cardiac Sarcoidosis.

  2025cites this paper
• Vericiguat Therapy Is Associated with Reverse Myocardial Remodeling in Chronic Heart Failure with Reduced Ejection Fraction

  2025cites this paper
• Left ventricular hypertrophy and myocardial fibrosis in heart failure with preserved ejection fraction: mechanisms and treatment

  2025cites this paper
• Effects of sacubitril/valsartan on cardiac remodeling in heart failure with reduced ejection fraction: An integrated study of molecular biomarkers and imaging techniques.

  2025cites this paper
• Impact of early in-hospital initiation of sacubitril/valsartan on left ventricular reverse remodelling in acute heart failure

  2025cites this paper
• The effect of cardiac resynchronization therapy on functional capacity based on cardiopulmonary exercise testing: a systematic review and meta-analysis

  2025cites this paper
• Reverse Remodelling, Myocardial Recovery and Remission in Heart Failure with Reduced Ejection Fraction: Clinical Implications and Management Strategies

  2025cites this paper
• The role of multi-modality imaging for the assessment of left atrium and left atrial appendage. A clinical consensus statement of the European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC).

  2025cites this paper
• Comparable Benefits in Heart Failure Hospitalization and Survival with Sacubitril/Valsartan Therapy in CRT Nonresponders and HFrEF Patients Without CRT Indication

  2025cites this paper
• Single Ascending-Dose Study of Selective ErbB4 Agonist JK07 in Heart Failure With Reduced Ejection Fraction

  2025cites this paper
• Improved risk assessment in parvovirus B19‐positive patients with heart failure by multiparametric analysis of endomyocardial biopsy using machine learning methods

  2025cites this paper
• Rationale, Design, and Baseline Characteristics of the Polypill for Heart Failure with Reduced Ejection Fraction (POLY-HF) Trial.

  2025cites this paper
• Late gadolinium-enhanced cardiovascular magnetic resonance for predicting left ventricular reverse remodeling in dilated cardiomyopathy: A comprehensive review and meta-analysis

  2025cites this paper
• Clinical research and trials in echocardiography: rationale, requirements and future opportunities

  2025cites this paper
• Left ventricular reverse remodeling: A predictor of survival in chagasic cardiomyopathy patients with a reduced ejection fraction

  2025cites this paper
• Cardiac Effects of Dapagliflozin in People with Chronic Kidney Disease.

  2025cites this paper
• Effect of SGLT2 inhibitors on cardiac structure and function assessed by cardiac magnetic resonance: a systematic review and meta-analysis

  2025cites this paper
• Predictors of Left Ventricular Reverse Remodeling in Heart Failure with Reduced Ejection Fraction

  2025cites this paper
• Molecular Imaging of Systemic Inflammatory Response in Lymphatic Organs Provides Prognostic Value after Re-Perfused Acute Myocardial Infarction

  2025cites this paper
• Left Ventricular Mass Index and Relative Wall Thickness Predict Atrial High‐Rate Episodes in Patients With Pacemaker Implantation

  2025cites this paper
• Mechanistic Basis for Differential Effects of Interatrial Shunt Treatment in HFrEF vs HFpEF: The RELIEVE-HF trial.

  2025cites this paper
• Right ventricular dysfunction for prediction of long‐term recovery in de novo HFrEF : a PROLONG‐II substudy

  2025cites this paper
• Ventricular remodeling and hemodynamic changes in heart failure patients with non-ischemic dilated cardiomyopathy following dapagliflozin initiation

  2024cites this paper
• Empagliflozin in the treatment of heart failure.

  2024cites this paper
• Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS‐MI): rationale and design

  2024cites this paper
• Cardiac Magnetic Resonance Evaluation of LV Remodeling Post-Myocardial Infarction: Prognosis, Monitoring and Trial Endpoints.

  2024cites this paper
• 20 years of treating ischemic cardiomyopathy with mesenchymal stromal cells: a meta-analysis and systematic review.

  2024cites this paper
• Effect of optimisation to contemporary HFrEF medical therapy with sacubitril/valsartan (Entresto) and dapaglifloziN on left Ventricular reverse remodelling as demonstrated by cardiac magnetic resonance (CMR) Imaging: the ENVI study

  2024cites this paper
• Cardiovascular outcomes and molecular targets for the cardiac effects of Sodium-Glucose Cotransporter 2 Inhibitors: A systematic review.

  2024cites this paper
• The impact of empagliflozin and metformin on cardiac parameters in patients with mid-range ejection fraction heart failure without diabetes

  2024cites this paper
• Left atrial conduit strain derived from cardiac magnetic resonance is an independent predictor of left ventricular reverse remodeling in patients with nonischemic cardiomyopathy

  2024cites this paper
• Management of congestive heart failure with heart transplantation using stem cell-derived cardiac muscle: a systematic review

  2024cites this paper
• Clinical and prognostic implications of left ventricular dilatation in heart failure.

  2024cites this paper
• Efficacy and safety of CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: Rationale and design of the HF‐REVERT trial

  2024cites this paper
• Heart failure with improved ejection fraction: Beyond diagnosis to trajectory analysis.

  2024cites this paper
• Echocardiographic Myocardial Work: A Novel Method to Assess Left Ventricular Function in Patients with Coronary Artery Disease and Diabetes Mellitus

  2024cites this paper
• The effect of sodium–glucose cotransporter 2 inhibitors on left cardiac remodelling in heart failure with reduced ejection fraction: Systematic review and meta‐analysis

  2024cites this paper
• Impact of angiotensin receptor-neprilysin inhibition (ARNI) in improving ejection fraction and left and right ventricular remodeling in heart failure.

  2024cites this paper
• Accurate fully automated assessment of left ventricle, left atrium, and left atrial appendage function from computed tomography using deep learning

  2024cites this paper
• Effects of sacubitril-valsartan on remodelling, fibrosis and mitochondria in a murine model of isoproterenol-induced left ventricular dysfunction.

  2024cites this paper
• Left Ventricular Reverse Remodeling after Successful Living Donor Kidney Transplantation

  2024cites this paper
• Echocardiography in the Assessment of Heart Failure Patients

  2024cites this paper
• Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction (EMPRESS‐MI)

  2024cites this paper
• Long-term surrogate cardiovascular outcomes of SGLT2 inhibitor empagliflozin in chronic heart failure: a systematic review and meta-analysis

  2024cites this paper
• Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

  2024cites this paper
• Unipolar Voltage Mapping to Predict Recovery of Left Ventricular Ejection Fraction in Patients With Recent-Onset Nonischemic Cardiomyopathy

  2024cites this paper
• Characteristics, outcomes and the necessity of continued guideline-directed medical therapy in patients with heart failure with improved ejection fraction

  2024cites this paper
• Device therapies for heart failure with reduced ejection fraction: a new era

  2024cites this paper
• High-sensitivity cardiac troponin I-guided combination angiotensin receptor blockade and beta blocker therapy to prevent anthracycline cardiotoxicity: the Cardiac CARE RCT

  2024cites this paper
• Effect of ertugliflozin on left ventricular function in type 2 diabetes and pre-heart failure: the Ertu-GLS randomized clinical trial

  2024cites this paper
• Efficacy and Safety of Omecamtiv Mecarbil in Adult Patients with Heart Failure with Reduced Ejection Fraction

  2024cites this paper
• Protocol-driven approach to guideline-directed medical therapy optimization for heart failure: A real-world application to recovery

  2024cites this paper
• Effect of empagliflozin on left ventricular volumes in type 2 diabetes or prediabetes heart failure patients with reduced ejection fraction

  2024cites this paper
• Role of Artificial Intelligence and Machine Learning to Create Predictors, Enhance Molecular Understanding, and Implement Purposeful Programs for Myocardial Recovery

  2024cites this paper
• Dynamic trajectories of left ventricular ejection fraction in heart failure with improved ejection fraction

  2024cites this paper
• Effect of henagliflozin on left ventricular mass index in dialysis patients with HFpEF (HELD-HF): protocol for a multicentre, randomised, double-blind, placebo-controlled trial

  2024cites this paper
• Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure.

  2024cites this paper
• Tissue inhibitor of metalloproteinase (TIMP)-1 predicts failure of recovery of ejection fraction in acute heart failure with reduced ejection fraction

  2024cites this paper
• Efficacy, Safety and Mechanistic Impact of a Heart Failure Guideline-Directed Medical Therapy Clinic.

  2024cites this paper
• Cardiovascular and Metabolic Effects of Modulating Circulating Ketone Bodies With 1,3‐Butanediol in Patients With Heart Failure With Reduced Ejection Fraction

  2024cites this paper
• Evaluation of Perfusion and Function in Cardiac Radionuclide Imaging in Cases of Heart Failure with Mid-Range Ejection Fraction

  2024cites this paper
• Ventricular Remodeling and Outcomes After Mitral Transcatheter Edge-to-Edge Repair in Heart Failure: The COAPT Trial.

  2023cites this paper
• Transcatheter left ventriculoplasty.

  2023cites this paper
• Effects of Atrioventricular Optimization on Left Ventricular Reverse Remodeling With Cardiac Resynchronization Therapy: Results of the SMART-CRT Trial

  2023cites this paper
• Paradoxes Continued: Treatment of Secondary MR and Impact on Ventricular Remodeling.

  2023cites this paper
• Cardiac reverse remodelling with vericiguat: Victory or no victory?

  2023cites this paper
• Exploring Ejection Fraction Range in Heart Failure Clinical Trials: Aid or Distraction for Personalized Treatment?

  2023cites this paper
• A review of current key guidelines for managing high‐risk patients with diabetes and heart failure and future prospects

  2023cites this paper
• New insights into the molecular mechanisms of SGLT2 inhibitors on ventricular remodeling.

  2023cites this paper
• A review of biomarker and imaging monitoring to predict heart failure recovery

  2023cites this paper
• Association of Depression and Anxiety with Cardiac Structural and Functional Characteristics in Heart Failure with Reduced and Mildly Reduced Ejection Fraction

  2023cites this paper
• Cardiac Myosin Activator Omecamtiv Mecarbil: Novel Treatment for Systolic Heart Failure

  2023cites this paper
• Clinical course and therapy optimisation of patients after discharge from a specialised heart failure clinic.

  2023cites this paper
• Big Endothelin-1 as a Predictor of Reverse Remodeling and Prognosis in Dilated Cardiomyopathy

  2023cites this paper
• Nationwide Temporal Trends in Clinical Characteristics and Treatment of Dilated Cardiomyopathy From 2003 to 2013 in Japan　- A Report From Clinical Personal Records.

  2023cites this paper
• Angiogenesis markers and reverse remodeling in patients with HFrEF.

  2023cites this paper
• The Association Between On-treatment Ambulatory Central Blood Pressure and Left Ventricular Reverse Remodeling in Heart Failure With Reduced Ejection Fraction

  2023cites this paper
• Prognosis after discontinuing renin angiotensin aldosterone system inhibitor for heart failure with restored ejection fraction after acute myocardial infarction

  2023cites this paper
• Assessment of left ventricular systolic function in patients with chronic coronary syndrome and heart failure with reduced ejection fraction after percutaneous coronary intervention

  2023cites this paper
• NOCTURNAL HYPOXIA INDEXES ARE ASSOCIATED WITH LEFT VENTRICULAR REMODELING AND DIASTOLIC DYSFUNCTION IN OBSTRUCTIVE SLEEP APNEA PATIENTS

  2023cites this paper
• [Effect of dapagliflozin on the dynamics of magnetic resonance imaging in patients with heart failure and atrial fibrillation].

  2023cites this paper
• Effect of SGLT-2 inhibitor, dapagliflozin, on left ventricular remodeling in patients with type 2 diabetes and HFrEF

  2023cites this paper
• Myocardial Recovery in Recent Onset Dilated Cardiomyopathy: Role of CDCP1 and Cardiac Fibrosis

  2023cites this paper
• Cardiac reverse remodelling by imaging parameters with recent changes to guideline medical therapy in heart failure

  2023cites this paper
• Effect of sacubitril/valsartan on cardiac remodeling compared with other renin–angiotensin system inhibitors: a difference-in-difference analysis of propensity-score matched samples

  2023influential citation
• The Pathophysiology and New Advancements in the Pharmacologic and Exercise-Based Management of Heart Failure With Reduced Ejection Fraction: A Narrative Review

  2023cites this paper
• Men are from Mars but women are not from Venus: The benefits of SGLT2 inhibitors after myocardial infarction are independent of gender.

  2023cites this paper
• Inward Displacement: A Novel Method of Regional Left Ventricular Functional Assessment for Left Ventriculoplasty Interventions in Heart Failure with Reduced Ejection Fraction (HFrEF)

  2023influential citation
• Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction: Real-World Experience from Italy (the REAL.IT Study)

  2023cites this paper